会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 35. 发明申请
    • Pharmaceutical compositions and methods for effecting dopamine release
    • 用于进行多巴胺释放的药物组合物和方法
    • US20040220214A1
    • 2004-11-04
    • US10454292
    • 2003-06-04
    • Targacept, Inc.
    • Merouane BencherifCraig Harrison MillerGregory D. HawkinsBalwinder S. Bhatti
    • C07D453/04A61K031/4745
    • A61K31/64C07D453/02C07D487/08Y02A50/469
    • Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia), are treated by administering a 1-aza-2-(3-pyridyl)bicyclonull2.2.1nullheptane, a 1-aza-2-(3-pyridyl)bicyclonull2.2.2nulloctane, a 1-aza-2-(3-pyridyl)bicyclonull3.2.1nulloctane, a 1-aza-2-(3-pyridyl)bicyclonull3.2.2nullnonane, a 1-aza-7-(3-pyridyl) bicyclonull2.2.1nullheptane, a 1-aza-3-(3-pyridyl)bicyclonull3.2.2nullnonane, or a 1-aza-7-(3-pyridyl)bicyclonull3.2.2nullnonane. The compounds can exist as individual stereoisomers, racemic mixtures, diastereomers and the like.
    • 特征在于正常神经递质释放(如多巴胺释放(如帕金森综合征,帕金森氏病,图雷特氏综合征,注意缺陷障碍或精神分裂症))改变的中枢神经系统疾病易患或患有疾病的患者是 通过施用1-氮杂-2-(3-吡啶基)双环[2.2.1]庚烷,1-氮杂-2-(3-吡啶基)双环[2.2.2]辛烷,1-氮杂-2- (3-吡啶基)双环[3.2.1]辛烷,1-氮杂-2-(3-吡啶基)双环[3.2.2]壬烷,1-氮杂-7-(3-吡啶基)双环[2.2.1 ]庚烷,1-氮杂-3-(3-吡啶基)双环[3.2.2]壬烷或1-氮杂-7-(3-吡啶基)双环[3.2.2]壬烷。 该化合物可作为单独的立体异构体,外消旋混合物,非对映异构体等存在。